Actavis, Others Plotted To Delay Generic Namenda, Suit Says

Law360, New York (June 9, 2015, 1:44 PM EDT) -- Actavis PLC and other pharmaceutical companies were hit with a proposed class action in New York federal court Monday over an alleged scheme to delay generic versions of the Alzheimer's drug Namenda, days after Actavis asked the Second Circuit to rethink an injunction related to the drug.

In its complaint, pension fund A.F. of L. - A.G.C. Building Trades Welfare Plan accused Actavis, its Forest Laboratories LLC unit as well as various generic manufacturers such as Amneal Pharmaceuticals LLC and Teva Pharmaceuticals USA Inc. of carrying out an unlawful scheme to maintain a monopoly in the market for memantine hydrochloride, which...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!